Comparative Pharmacology
Head-to-head clinical analysis: AFRINOL versus MOTPOLY XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFRINOL versus MOTPOLY XR.
AFRINOL vs MOTPOLY XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.
MOTPOLY XR is a combination of an opioid agonist (morphine) and an opioid antagonist (naltrexone). The extended-release formulation allows for sequential release: an initial morphine dose followed by naltrexone, which mitigates opioid-induced adverse effects by antagonizing mu-opioid receptors in the gastrointestinal tract without affecting central analgesia.
Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.
Adults: 10 mg orally once daily, with or without food.
None Documented
None Documented
9–11 hours in healthy adults; prolonged to 16–18 hours in hepatic cirrhosis and up to 20 hours in severe renal impairment. Clinical context: dosing interval typically 12 hours in normal renal function.
Terminal half-life 12–15 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min).
Renal (approximately 70–90% as unchanged drug and metabolites), with about 10% biliary/fecal elimination. Dose adjustment required in renal impairment (CrCl <30 mL/min).
Renal: ~60% unchanged; biliary/fecal: ~25% as metabolites; <5% unchanged in feces.
Category C
Category C
Decongestant
Decongestant/Antihistamine Combination